Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged
283 Views06 May 2021 08:56
As Guangzhou Pharmaceuticals submitted the IPO application, the risk points emerged considering the competition pattern, new policies and business performance, revealing the true logic behind of IPO.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO Hangzhou Bioer Technology - Concerns Behind the Outstanding Performance20 Jul 2021
- Pre-IPO Broncus Holding Corporation - The Strength and the Concerns30 Jun 2021
- Pre-IPO Keymed Biosciences - Challenges Are Inevitable Despite Some Advantages on Pipeline11 May 2021
- Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged06 May 2021
- Pre-IPO Beijing Keya Medical Technology - Here Are the Strength and the Concerns21 Apr 2021
- Pre-IPO YishengBio Co., Ltd - Here Are the Concerns Despite Solid Market Potential15 Apr 2021
- Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy22 Oct 2020
x